Valacyclovir: An overview
- Kimon C Zachary, MD
Kimon C Zachary, MD
- Assistant Professor of Medicine
- Harvard Medical School
Valacyclovir is the valyl ester of the antiviral drug acyclovir . Acting as an oral prodrug, valacyclovir is converted in vivo to acyclovir. Acyclovir, a nucleoside analog, is phosphorylated by virally-encoded thymidine kinase and subsequently by cellular enzymes, yielding acyclovir triphosphate, which competitively inhibits viral DNA polymerase. (See "Acyclovir: An overview".)
The antiviral activity of valacyclovir reflects its in vivo conversion to acyclovir, which is active against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at the oral doses approved by the US Food and Drug Administration [2,3].
Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than acyclovir; it then undergoes rapid and extensive first-pass intestinal and/or hepatic hydrolysis to yield acyclovir and L-valine [2,3]. Food does not affect absorption.
Valacyclovir, at a dose of 250 mg four times daily, generates essentially the same acyclovir AUC (area under the curve, or exposure over 24 hours) as oral acyclovir at a dose 800 mg five times daily . Valacyclovir, at a dose of 1000 mg three times daily, produces a similar acyclovir AUC as intravenous acyclovir at a dose of 5 mg/kg every eight hours .
Intravenous acyclovir generates higher peak levels than oral valacyclovir. Although this feature may confer more potent activity, it may also increase the risk of renal toxicity due to precipitation of acyclovir crystals in the renal tubules  (see "Crystal-induced acute kidney injury (acute renal failure)"). On the other hand, the safety of high-dose oral valacyclovir, especially in immunocompromised persons, remains controversial.
Subscribers log in hereLiterature review current through: Aug 2017. | This topic last updated: Nov 08, 2016.References
- Valtrex (valacyclovir hydrochloride) prescribing information, Glaxo Wellcome Inc, 2013. https://www.gsksource.com/gskprm/htdocs/documents/VALTREX-PI-PIL.PDF.
- Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs 1996; 52:17.
- Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754.
- Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47:855.
- Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.
- Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.
- Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.